Radium-223 xofigo
Ended Awarded Last action
- Contract number
- 36C25024F0292
- Awardee
-
Bayer Healthcare Pharmaceuticals Inc. UEI V1EVGCK7XES8 Part of Bayer Aktiengesellschaft
- Awarding agency
-
Veterans Integrated Service Network 10
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $50,605
Award facts
- Contract value 100% obligated
- $50,604.87 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Dublin, OH 43017, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$34,416 | |
| Other Administrative Action | $0 | |
| Original award | $85,021 |
About this award
Bayer Healthcare Pharmaceuticals Inc., a subsidiary of Bayer AG, received a delivery order valued at $50,604.87 from the Department of Veterans Affairs (Veterans Integrated Service Network 10) for Radium-223 Xofigo, a radiopharmaceutical used in prostate cancer treatment. Awarded on January 3, 2024, with an ultimate completion date of January 2, 2025, this contract was issued under a firm fixed-price arrangement with no small business set-aside designation. The delivery order will be performed in Dublin, Ohio, and represents a continuation of Bayer's long-standing relationship supplying specialized pharmaceuticals to the VA.
This delivery order falls under Bayer Healthcare Pharmaceuticals Inc.'s broader Federal Supply Schedule contract (FSS-61-IB) for Pharmaceuticals and Drugs with the VA, an $840 million multiple-award vehicle that enables federal agencies to procure essential medications. Additionally, the company maintains a $6.8 million blanket purchase agreement with the VA National Acquisition Center specifically covering Xofigo and Adempas procurement through October 2026. These indefinite delivery vehicles streamline the VA's ability to rapidly acquire critical cancer therapeutics and other specialized medications needed to support comprehensive healthcare programs for veterans.
Quick answers
Who was awarded contract 36C25024F0292?
36C25024F0292 was awarded to Bayer Healthcare Pharmaceuticals Inc. by Veterans Integrated Service Network 10 (Veterans Health Administration) on January 3, 2024.
How much is contract 36C25024F0292 worth?
The government has obligated $50,605 on 36C25024F0292.
Is contract 36C25024F0292 an order under another contract?
Yes. 36C25024F0292 is a delivery order under 36F79720D0237, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25024F0292 competed?
The extent of competition for 36C25024F0292 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award